Literature DB >> 11157649

Antithrombotic therapy in atrial fibrillation.

G W Albers1, J E Dalen, A Laupacis, W J Manning, P Petersen, D E Singer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11157649     DOI： 10.1378/chest.119.1_suppl.194s

Source DB:  PubMed          Journal:  Chest        ISSN： 0012-3692            Impact factor:   9.410


× No keyword cloud information.
  68 in total

1.  Letters, numbers, symbols and words: how to communicate grades of evidence and recommendations.

Authors:  Holger J Schünemann; Dana Best; Gunn Vist; Andrew D Oxman
Journal:  CMAJ       Date:  2003-09-30       Impact factor: 8.262

Review 2.  Determination of the clinical importance of study results.

Authors:  Malcolm Man-Son-Hing; Andreas Laupacis; Keith O'Rourke; Frank J Molnar; Jeffery Mahon; Karen B Y Chan; George Wells
Journal:  J Gen Intern Med       Date:  2002-06       Impact factor: 5.128

Review 3.  Why is warfarin underutilized in patients with atrial fibrillation?

Authors:  Greg C Flaker; John Schutz
Journal:  J Interv Card Electrophysiol       Date:  2004       Impact factor: 1.900

Review 4.  Randomized trials of rate vs. rhythm control for atrial fibrillation.

Authors:  Mina K Chung
Journal:  J Interv Card Electrophysiol       Date:  2004       Impact factor: 1.900

Review 5.  Atrial fibrillation: classification, pathophysiology, mechanisms and drug treatment.

Authors:  Vias Markides; Richard J Schilling
Journal:  Heart       Date:  2003-08       Impact factor: 5.994

6.  Warfarin for non-valvar atrial fibrillation: still underused in the 21st century?

Authors:  S Bo; G Ciccone; L Scaglione; C Taliano; M Piobbici; F Merletti; G Pagano
Journal:  Heart       Date:  2003-05       Impact factor: 5.994

Review 7.  The management of patients who require temporary reversal of vitamin K antagonists for surgery: a practical guide for clinicians.

Authors:  Caterina Mannucci; James D Douketis
Journal:  Intern Emerg Med       Date:  2006       Impact factor: 3.397

Review 8.  New anticoagulants: beyond heparin, low-molecular-weight heparin and warfarin.

Authors:  Shannon M Bates; Jeffrey I Weitz
Journal:  Br J Pharmacol       Date:  2005-04       Impact factor: 8.739

Review 9.  Recent developments in atrial fibrillation.

Authors:  M Bilal Iqbal; Anil K Taneja; Gregory Y H Lip; Marcus Flather
Journal:  BMJ       Date:  2005-01-29

Review 10.  Thyroid, hemostasis and thrombosis.

Authors:  F Marongiu; C Cauli; S Mariotti
Journal:  J Endocrinol Invest       Date:  2004-12       Impact factor: 4.256
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.